TCGA-CV-7102-01A-11R-2016-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.012785388
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- MYOGENESIS+0.530
- G2M_CHECKPOINT+0.480
- HEDGEHOG_SIGNALING+0.470
- E2F_TARGETS+0.460
- MITOTIC_SPINDLE+0.370
- APICAL_JUNCTION+0.320
- PANCREAS_BETA_CELLS+0.310
- UV_RESPONSE_DN+0.310
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.400
- TNFA_SIGNALING_VIA_NFKB-0.350
- INTERFERON_GAMMA_RESPONSE-0.290
- OXIDATIVE_PHOSPHORYLATION-0.270
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.270
- CHOLESTEROL_HOMEOSTASIS-0.220
- UV_RESPONSE_UP-0.220
- FATTY_ACID_METABOLISM-0.160
- PEROXISOME-0.100
- MYC_TARGETS_V2-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-A8-A07E-01A-11R-A034-07 | — | A | 0.785 |
| 2 | TCGA-BH-A0AV-01A-31R-A115-07 | — | E | 0.756 |
| 3 | DRR168609 | — | — | 0.754 |
| 4 | TCGA-CN-6022-01A-21R-1686-07 | — | — | 0.749 |
| 5 | c45adda2-fffe-4add-8148-01ecf35dd855 | — | — | 0.738 |
| 6 | SRR5903555 | — | cohortSQ1 | 0.736 |
| 7 | TCGA-CR-7365-01A-11R-2016-07 | — | — | 0.728 |
| 8 | TCGA-AR-A24Q-01A-12R-A169-07 | — | E | 0.720 |
| 9 | TCGA-55-7726-01A-11R-2170-07 | — | cohortSQ1 | 0.720 |
| 10 | R211 | — | — | 0.713 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 34 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.550 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| MYOGENESIS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.480 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.470 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.460 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.370 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.310 | Inavolisib | — uncovered |
| COAGULATION | 0.280 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.210 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.170 | Remibrutinib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.160 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.130 | Inavolisib | — uncovered |